Especially when combined with a BCL2 and/or BCL6 rearrangement (high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement), these DLBCL have a poor outcome when treated with standard R-CHOP chemotherapy [2], and may require a different treatment [3]. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.